Company Encyclopedia
View More
name
Fortress Biotech
FBIO.US
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company’s early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator.
1.945 T
FBIO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking281/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-13.86%E
    • Profit Margin6.40%B
    • Gross Margin66.18%A
  • Growth ScoreC
    • Revenue YoY-23.56%E
    • Net Profit YoY90.72%A
    • Total Assets YoY42.74%A
    • Net Assets YoY611.74%A
  • Cash ScoreE
    • Cash Flow Margin-1167.60%E
    • OCF YoY-23.56%E
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreD
    • Gearing Ratio64.07%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA

    Fortress Biotech Inc :FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDAFORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES & UP TO $129 MILLION IN MILESTONES

    Reuters·
    US
    FBIO
    +4.00%
    Reuters·
    US
    FBIO
    +4.00%

    Fortress Biotech’s Earnings Call Highlights EMROSI Success

    Fortress Biotech's Q3 earnings call highlighted significant revenue growth driven by EMROSI's success, despite challenges like declining legacy product revenues and formulary adoption delays. Journey Medical reported a 21% revenue increase, with EMROSI contributing $4.9 million. The company improved EBITDA and expanded market access. Despite a slight gross margin decrease, Fortress Biotech remains optimistic, expecting sustainable EBITDA positivity by Q4 and peak annual net sales over $200 million in the U.S. and $300 million globally for EMROSI.

    Tip Ranks·
    US
    FBIO
    +4.00%
    Tip Ranks·
    US
    FBIO
    +4.00%

    Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of ...

    GlobeNewswire·
    US
    FBIO
    +4.00%
    GlobeNewswire·
    US
    FBIO
    +4.00%

    Fortress Biotech, Inc. SEC 10-Q Report

    Fortress Biotech, Inc. released its Q3 2025 10-Q report, showing significant financial and operational improvements. Net revenue rose to $17.6 million, and net income reached $8.8 million, reversing a previous loss. Key drivers included increased product sales and strategic initiatives. The company expanded its market in China and launched new products, with plans for further development and growth. The report highlights enhanced profitability and operational efficiency.

    TradingView·
    US
    FBIO
    +4.00%
    TradingView·
    US
    FBIO
    +4.00%

    Fortress Biotech | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 17.63 M

    LB filings·
    US
    FBIO
    +4.00%
    LB filings·
    US
    FBIO
    +4.00%
    © 2025 Longbridge｜Disclaimer